Candesartan Mitigates Paclitaxel-Induced Peripheral Neuropathy in Human Neuron Cells: A Comprehensive in Vitro Evaluation
DOI:
https://doi.org/10.31351/vol33iss(4SI)pp67-76Abstract
Paclitaxel (Taxol) belongs to the initial taxane category and is employed for treating diverse types of cancers, including ovarian, lung, and breast cancers. Paclitaxel is associated with the highest prevalence of peripheral neuropathy. The detection of PIPN may necessitate a reduction in dosage or discontinuation of treatment, which can have consequences for cancer care. Activation of AT2R has shown neuroprotective effects in different rodent models. this study aims to assess the potential impact of candesartan in mitigating the deleterious effect on human neuron cells. The methods involved in Immunocytochemistry to characterize the neuron cells depend on the expression of the B tubulin III protein. WST-8 test was used on human neuron cell culture to assess the individual and combined cytotoxicity and inhibition ratio (IR%) of Taxol and candesartan. The Chou-Talalay index (CI) equation was utilized to determine if the interaction was antagonistic, additive, or synergistic. As well as investigating the morphological change. The results, findings demonstrated a notable increase in the inhibitory ratio (IR%) when comparing Taxol to the control group at all serial concentrations, with statistical significance (P<0.05). on the other hand, candesartan did not show any significant difference compared to the control group (P>0.05). Interestingly, the combination treatment group showed a significant reduction in the inhibitory ratio (IR%) when compared to the Taxol group. the estimated Chou-Talalay indices (CI) values suggest a significant antagonistic interaction between Taxol and candesartan at different dosages in sequential concentrations (CI>1.1).The morphology imaging of neuron cells after treatment reveals enhanced neuronal cell morphology when using combination Taxol and candesartan. In conclusion, candesartan exhibits the potential to mitigate the cytotoxicity effect of Taxol chemotherapy.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Saad AH, Salih H. Adherence and Beliefs to Adjuvant Hormonal Therapy in Patients with Breast Cancer: A Cross-Sectional Study (Conference Paper). Iraqi Journal of Pharmaceutical Sciences.2021. 30(Suppl.), 31-39.
Salah Rabeea I, Abdul Baqi Al Dujeli A, Abdul Jabbar Rizij F, & Ali Hussein A. Effect of zinc sulfate on kidney function in cisplatin-treated cancer patients. Kerbala Journal of Medicine.2016. 9(2), 2505-2512.
Klein I, & Lehmann HC. Pathomechanisms of paclitaxel-induced peripheral neuropathy. Toxics.2021. 9(10), 229.
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, & Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. International Journal of Molecular Sciences. 2019. 20(6), 1451.
Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, & Balayssac D. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Frontiers in pharmacology.2017. 8, 86.
Fukuda Y, Li Y, Segal RA. A Mechanistic Understanding of Axon Degeneration in Chemotherapy-Induced Peripheral Neuropathy. Front Neurosci.2017. 11, 481.
Smith JA, Slusher BS, Wozniak KM, Farah MH, Smiyun G, Wilson L, Feinstein S, Jordan MA. Structural Basis for Induction of Peripheral Neuropathy by Microtubule-Targeting Cancer Drugs. Cancer Res.2016. 76, 5115–5123.
Bobylev I, Joshi AR, Barham M, Ritter C, Neiss WF, Höke A, Lehmann HC, Paclitaxel inhibits mRNA transport in axons. Neurobiol Dis.2015. 82, 321–331.
Chiba T, Oka Y, Kambe T, Koizumi N, Abe K, Kawakami K, Utsunomiya I, Taguchi K. Paclitaxel-induced peripheral neuropathy increases substance P release in rat spinal cord. Eur J Pharmacol.2016. 770, 46–51.
Li L, Li J, Zuo Y, Dang D, Frost JA, Yang Q. Activation of KCNQ Channels Prevents Paclitaxel-Induced Peripheral Neuropathy and Associated Neuropathic Pain. The Journal of Pain: Official Journal of the American Pain Society.2019. 20, 528–539.
Li Y, North RY, Rhines LD, Tatsui CE, Rao G, Edwards DD, Cassidy RM, Harrison DS, Johansson CA, Zhang H, Dougherty PM. DRG Voltage-Gated Sodium Channel 1.7 Is Upregulated in Paclitaxel-Induced Neuropathy in Rats and Humans with Neuropathic Pain. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience.2018. 38, 1124–1136.
Pease-Raissi SE, Pazyra-Murphy MF, Li Y, Wachter F, Fukuda Y, Fenstermacher SJ, Barclay LA, Bird GH, Walensky LD, Segal RA. Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration—neuron .2017.96, 373–386 e376.
Sekiguchi F, Domoto R, Nakashima K, Yamasoba D, Yamanishi H, Tsubota M, Wake H, Nishibori M, Kawabata A. Paclitaxel-induced HMGB1 release from macrophages and its implication for peripheral neuropathy in mice: Evidence for a neuroimmune crosstalk. Neuropharmacology .2018.141, 201–213.
Matthewman C, Miller-Fleming TW, Miller 3rd DM, & Bianchi, L. Ca2+ permeability and Na+ conductance in cellular toxicity caused by hyperactive DEG/ENaC channels. American Journal of Physiology-Cell Physiology.2016.311(6), C920-C930.
Danigo A, Rovini A, Bessaguet F, Bouchenaki H, Bernard A, Sturtz F, ... & Demiot C. The angiotensin II type 2 receptor, is a target for protection and regeneration of the peripheral nervous system. Pharmaceuticals.2021. 14(3), 175.
Hegazy N, Rezq S, & Fahmy A. Renin‐angiotensin system blockade modulates both the peripheral and central components of neuropathic pain in rats: Role of calcitonin gene-related peptide, substance P and nitric oxide. Basic & Clinical Pharmacology & Toxicology.2020.127(6), 451-460.
Bouchenaki H, Bernard A, Bessaguet F, Frachet S, Richard L, Sturtz F, & Danigo A. Neuroprotective Effect of Ramipril Is Mediated by AT2 in a Mouse MODEL of Paclitaxel-Induced Peripheral Neuropathy. Pharmaceutics.2022. 14(4),848.
Alkhudhayri S, Sajini R, Alharbi B, Qabbani J, Al‐Hindi Y, Fairaq A, & Yousef A. Investigating the beneficial effect of aliskiren in attenuating neuropathic pain in diabetic Sprague‐Dawley rats. Endocrinology, Diabetes & Metabolism.2021. 4(2), e00209.
Petropoulos IN, Ponirakis G, Ferdousi M, Azmi S, Kalteniece A, Khan A, & Malik RA. Corneal confocal microscopy: a biomarker for diabetic peripheral neuropathy. Clinical therapeutics.2021. 43(9), 1457-1475.
Timaru-Kast R, Garcia Bardon A, Luh C, Coronel-Castello SP, Songarj P, Griemert EV, & Thal SC. AT2 activation does not influence brain damage in the early phase after experimental traumatic brain injury in male mice. Scientific Reports 2022. 12(1), 14280.
Bennion DM, Isenberg JD, Harmel AT, DeMars K, Dang AN, Jones CH, & Sumners C. Post-stroke angiotensin II type 2 receptor activation provides long-term neuroprotection in aged rats. PLoS One.2017. 12(7), e0180738.
Fouda AY, Ahmed HA, Pillai B, Kozak A, Hardigan T, Ergul A, & Ishrat T. Contralesional angiotensin type 2 receptor activation contributes to recovery in experimental stroke. Neurochemistry International.2022.158, 105375.
Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from breast carcinoma. J Natl Cancer Inst. 1973 Nov;51(5):1409-16.
Fang T, Yin X, Wang Y, Wang H, Wang X, Xue Y. Lymph node metastasis-related gene ITGA4 promotes the proliferation, migration, and invasion of gastric cancer cells by regulating tumor immune microenvironment. J Oncol (2022) 2022:1315677.
Del Gaudio N, Di Costanzo A, Liu NQ, Conte L, Dell'Aversana C, Bove G, & Altucci L. CBX2 shapes chromatin accessibility promoting AML via the p38 MAPK signaling pathway. Molecular Cancer.2022. 21(1), 1-15.
Liu Y, Chang D, & Zhou X. Development of Novel Herbal Compound Formulations Targeting Neuroinflammation: Network Pharmacology, Molecular Docking, and Experimental Verification. Evidence-Based Complementary and Alternative Medicine. 2023.doi: 10.1155/2023/2558415. PMID: 37266321; PMCID: PMC10232107.
Chang YC, Lo YC, Chang HS, Lin HC, Chiu CC, & Chen YF. An efficient cellular image-based platform for high-content screening of neuroprotective agents against chemotherapy-induced neuropathy. NeuroToxicology.2023.96, 118-128.
Duregon F, Vendramin B, Bullo V, Gobbo S, Cugusi L, Di Blasio A, & Ermolao A. Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: a systematic review. Critical reviews in oncology/hematology.2018. 121, 90-100.
Stage TB, Bergmann TK, & Kroetz DL. Clinical pharmacokinetics of paclitaxel monotherapy: an updated literature review. Clinical pharmacokinetics.2018. 57(1), 7-19.
Bessaguet F, Danigo A, Bouchenaki H, Duchesne M, Magy L, Richard L, ... & Demiot C. Neuroprotective effect of angiotensin II type 2 receptor stimulation in vincristine-induced mechanical allodynia. Pain.2018. 159(12), 2538-2546.
Blanco H M, Perez CN, Bianchi C, Alvarez SE, & Ciuffo GM. Neurite outgrowth induced by stimulation of angiotensin II AT2 receptors in SH-SY5Y neuroblastoma cells involves c-Src activation. Heliyon.2023. 9(5).
Guimond M O, Wallinder C, Alterman M, Hallberg A, & Gallo-Payet N. Comparative functional properties of two structurally similar selective nonpeptide drug-like ligands for the angiotensin II type-2 (AT2) receptor. Effects on neurite outgrowth in NG108-15 cells. European Journal of pharmacology.2013. 699(1-3), 160-171.
Meffert S., Stolf M., Steckelings U.M., Bottari S.P., Unger T. The Angiotensin II AT2 Receptor Inhibits Proliferation and Promotes Differentiation in PC12W Cells. Mol. Cell. Endocrinol. 1996;122:59–67.
Bessaguet F, Danigo A, Magy L, Sturtz F, Desmoulière A, & Demiot C. Candesartan prevents resiniferatoxin-induced sensory small-fiber neuropathy in mice by promoting angiotensin II-mediated AT2 receptor stimulation. Neuropharmacology.2017. 126, 142-150.
Hobara N, Goda M, Yoshida N, Takatori S, Kitamura Y, Mio M, & Kawasaki H. Angiotensin II type 2 receptors facilitate reinnervation of phenol-lesioned vascular calcitonin gene-related peptide-containing nerves in rat mesenteric arteries. Neuroscience.2007. 150(3), 730-741.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
